StreetInsider.com News Articles

InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference

Thu, 26 Feb 2026 07:30:00 -0500

JENA, Germany, Feb. 26, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in the Leerink Partners Global Healthcare Conference. Details are as follows:

Leerink Partners Global Healthcare Conference
March 8 - 11, 2026 in Miami, FL
Fireside chat on March 9 at 9:20 AM ET

InflaRx will also conduct one-on-one investor meetings on March 9th. A link to view the fireside chat live stream and its replay is available here.

InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference

Thu, 26 Feb 2026 07:30:00 -0500

Leerink Partners Global Healthcare Conference
March 8 - 11, 2026 in Miami, FL
Fireside chat on March 9 at 9:20 AM ET

InflaRx will also conduct one-on-one investor meetings on March 9th. A link to view the fireside chat live stream and its replay is available here.

InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference

Thu, 26 Feb 2026 07:30:00 -0500

Leerink Partners Global Healthcare Conference
March 8 - 11, 2026 in Miami, FL
Fireside chat on March 9 at 9:20 AM ET

InflaRx will also conduct one-on-one investor meetings on March 9th. A link to view the fireside chat live stream and its replay is available here.

InflaRx Announces Participation in the Leerink Partners Global Healthcare Conference

Thu, 26 Feb 2026 07:30:00 -0500

Leerink Partners Global Healthcare Conference
March 8 - 11, 2026 in Miami, FL
Fireside chat on March 9 at 9:20 AM ET

InflaRx will also conduct one-on-one investor meetings on March 9th. A link to view the fireside chat live stream and its replay is available here.

iFOREX Lists on the London Stock Exchange

Wed, 25 Feb 2026 03:00:00 -0500

LIMASSOL, Cyprus--(BUSINESS WIRE)-- iFOREX proudly marks a major milestone with its official listing on the Main Market of the London Stock Exchange under the ticker IFRX, at a valuation of £43.3 million. This landmark achievement represents a significant step forward in iFOREX’s journey toward becoming a global fintech market leader, bringing fresh innovation and expanded opportunities directly to retail traders.

For almost 30 years, iFOREX’s commitment to innovation and disciplined risk management has driven consistent profitability, underpinned by its proprietary technology. By combining advanced trading technology with exceptional customer service, the company continues to meet the evolving needs

iFOREX Lists on the London Stock Exchange

Wed, 25 Feb 2026 03:00:00 -0500

Form SCHEDULE 13G/A InflaRx N.V. Filed by: SUVRETTA CAPITAL MANAGEMENT, LLC

Fri, 13 Feb 2026 16:33:00 -0500

si-local-file:///var/storage/secattach/20260213/26001154.html

Form SCHEDULE 13G/A InflaRx N.V. Filed by: SUVRETTA CAPITAL MANAGEMENT, LLC

Fri, 13 Feb 2026 16:33:00 -0500

si-local-file:///var/storage/secattach/20260213/26001154.html

InflaRx Announces Participation in February Investor Conferences

Thu, 29 Jan 2026 07:30:00 -0500

JENA, Germany, Jan. 29, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it will participate in several investor conferences in February 2026. Details are as follows:

Guggenheim Securities Emerging Outlook: Biotech Summit 2026
February 11 - 12, 2026 in New York, NY
Fireside chat on Wednesday, February 11 at 11:30 AM ET

InflaRx will also conduct one-on-one investor meetings on February 11^th. A link to view the fireside chat live stream and its replay is available here.

InflaRx Announces Participation in February Investor Conferences

Thu, 29 Jan 2026 07:30:00 -0500

Guggenheim Securities Emerging Outlook: Biotech Summit 2026
February 11 - 12, 2026 in New York, NY
Fireside chat on Wednesday, February 11 at 11:30 AM ET

InflaRx will also conduct one-on-one investor meetings on February 11^th. A link to view the fireside chat live stream and its replay is available here.

InflaRx Announces Participation in February Investor Conferences

Thu, 29 Jan 2026 07:30:00 -0500

Guggenheim Securities Emerging Outlook: Biotech Summit 2026
February 11 - 12, 2026 in New York, NY
Fireside chat on Wednesday, February 11 at 11:30 AM ET

InflaRx will also conduct one-on-one investor meetings on February 11^th. A link to view the fireside chat live stream and its replay is available here.

InflaRx Announces Participation in February Investor Conferences

Thu, 29 Jan 2026 07:30:00 -0500

Guggenheim Securities Emerging Outlook: Biotech Summit 2026
February 11 - 12, 2026 in New York, NY
Fireside chat on Wednesday, February 11 at 11:30 AM ET

InflaRx will also conduct one-on-one investor meetings on February 11^th. A link to view the fireside chat live stream and its replay is available here.

Form 6-K InflaRx N.V. For: Jan 08

Thu, 08 Jan 2026 16:06:00 -0500

si-local-file:///var/storage/secattach/20260108/25826686.html

Form 6-K InflaRx N.V. For: Jan 08

Thu, 08 Jan 2026 16:06:00 -0500

si-local-file:///var/storage/secattach/20260108/25826686.html

InflaRx cuts 30% of workforce to focus on izicopan development

Thu, 08 Jan 2026 08:11:14 -0500

InflaRx N.V. (NASDAQ: IFRX) announced a workforce reduction of approximately 30% and substantial spending cuts as the biopharmaceutical company refocuses its resources on developing izicopan for hidradenitis suppurativa and other inflammation and immunology indications.

The restructuring includes significant reductions in spending on Gohibic (vilobelimab) commercial activities and related functions. The company estimates these actions will result in a one-time charge of approximately $7 million, with the majority being a non-cash charge related to vilobelimab inventory write-offs.

The German-based company expects the cost reductions to extend its cash runway to mid-2027. InflaRx will maintain operational capability to support the ongoing BARDA "Just Breathe"

InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation

Thu, 08 Jan 2026 08:00:00 -0500

InflaRx to prioritize izicopan as its leading pipeline asset, with a goal of continuing toward Phase 2b readiness in hidradenitis suppurativa (HS)
To broaden signal-finding activities for izicopan in additional I&I (inflammation and immunology) indications, InflaRx intends to conduct a PK bridging study in China in 2026 to enable expedited proof of concept studies in China and additional geographies
Toward the goal of fast-tracking izicopan development across all applicable I&I indications, InflaRx continues its concurrent strategy to foster discussions with potential collaborators
InflaRx is executing an approximately 30% workforce reduction, leading to a significant reduction of the Company’s

InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation

Thu, 08 Jan 2026 08:00:00 -0500

InflaRx to prioritize izicopan as its leading pipeline asset, with a goal of continuing toward Phase 2b readiness in hidradenitis suppurativa (HS)
To broaden signal-finding activities for izicopan in additional I&I (inflammation and immunology) indications, InflaRx intends to conduct a PK bridging study in China in 2026 to enable expedited proof of concept studies in China and additional geographies
Toward the goal of fast-tracking izicopan development across all applicable I&I indications, InflaRx continues its concurrent strategy to foster discussions with potential collaborators
InflaRx is executing an approximately 30% workforce reduction, leading to a significant reduction of the Company’s

InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation

Thu, 08 Jan 2026 08:00:00 -0500

InflaRx to prioritize izicopan as its leading pipeline asset, with a goal of continuing toward Phase 2b readiness in hidradenitis suppurativa (HS)
To broaden signal-finding activities for izicopan in additional I&I (inflammation and immunology) indications, InflaRx intends to conduct a PK bridging study in China in 2026 to enable expedited proof of concept studies in China and additional geographies
Toward the goal of fast-tracking izicopan development across all applicable I&I indications, InflaRx continues its concurrent strategy to foster discussions with potential collaborators
InflaRx is executing an approximately 30% workforce reduction, leading to a significant reduction of the Company’s

InflaRx Announces Strategy Focused on Capital-Efficient Execution with Izicopan and Near-Term Value Creation

Thu, 08 Jan 2026 08:00:00 -0500

InflaRx to prioritize izicopan as its leading pipeline asset, with a goal of continuing toward Phase 2b readiness in hidradenitis suppurativa (HS)
To broaden signal-finding activities for izicopan in additional I&I (inflammation and immunology) indications, InflaRx intends to conduct a PK bridging study in China in 2026 to enable expedited proof of concept studies in China and additional geographies
Toward the goal of fast-tracking izicopan development across all applicable I&I indications, InflaRx continues its concurrent strategy to foster discussions with potential collaborators
InflaRx is executing an approximately 30% workforce reduction, leading to a significant reduction of the Company’s

Raymond James on Inflarx NV (IFRX): 'analyses of the unblinded Phase 3 dataset for vilobelimab...suggests evidence of a positive trend'

Wed, 31 Dec 2025 06:37:26 -0500

Raymond James analyst Ryan Deschner reiterated an Outperform rating and $9.00 price target on Inflarx NV (NASDAQ: IFRX).

The analyst comments "New post-hoc analyses of the unblinded Phase 3 dataset for vilobelimab (anti-C5a mAb) in pyoderma gangrenosum (PG) suggests evidence of a positive trend in treatment effect, particularly in terms of target ulcer volume. Despite the interim primary endpoint analysis showing a non-statistically significant complete target ulcer closure response (20.8% vs. 16.7% placebo), post-hoc MMRM analysis of percent change in target ulcer volume showed average effect over all visits favored vilobelimab over placebo (-45.4%, p =0.0428). The improvement trend in ulcer

Raymond James on Inflarx NV (IFRX): 'analyses of the unblinded Phase 3 dataset for vilobelimab...suggests evidence of a positive trend'

Wed, 31 Dec 2025 06:37:26 -0500

Raymond James analyst Ryan Deschner reiterated an Outperform rating and $9.00 price target on Inflarx NV (NASDAQ: IFRX).

Form 6-K InflaRx N.V. For: Dec 30

Tue, 30 Dec 2025 07:57:00 -0500

si-local-file:///var/storage/secattach/20251230/25788137.html

Form 6-K InflaRx N.V. For: Dec 30

Tue, 30 Dec 2025 07:57:00 -0500

si-local-file:///var/storage/secattach/20251230/25788137.html

InflaRx sees signals of efficacy in vilobelimab pyoderma gangrenosum trial

Tue, 30 Dec 2025 07:30:21 -0500

InflaRx N.V. (NASDAQ: IFRX) reported additional analyses of its Phase 3 trial for vilobelimab in pyoderma gangrenosum, which was terminated earlier this year after failing to meet its primary endpoint.

The company said post-hoc analyses revealed signals suggesting a treatment effect for vilobelimab compared to placebo. The trial enrolled 54 patients before termination, with 30 patients completing six months of treatment.

The primary endpoint of complete target ulcer closure showed 20.8% of vilobelimab patients achieving the goal versus 16.7% for placebo, a difference that was not statistically significant. Complete disease remission occurred in 20.8% of vilobelimab patients compared to 5.6% of placebo

InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum

Tue, 30 Dec 2025 07:30:00 -0500

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), subsequent post-hoc analyses suggest a positive trend in favor of vilobelimab, with signals indicating a potentially consistent treatment effect
InflaRx anticipates meeting with the FDA to determine a potential development path forward in PG, which the Company anticipates would only be conducted in collaboration with a partner

JENA, Germany, Dec. 30, 2025 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by